Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants".
作者信息
Gómez Jorge A, Pinto Thatiana de Jesus Pereira, Guevara Javier Nieto, Noronha Tatiana Guimarães de
机构信息
Vaccine Department, GlaxoSmithKline, Buenos Aires, Argentina.
Vaccine Department, GlaxoSmithKline, Rio de Janeiro, Brazil.
出版信息
Hum Vaccin Immunother. 2022 Dec 31;18(1):1894898. doi: 10.1080/21645515.2021.1894898. Epub 2021 May 19.
Abstract
摘要
相似文献
1
Response to article by Johnna Perdrizet et al.,"Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants".对约翰娜·佩德里泽特等人所著文章《巴西婴儿用13价肺炎球菌结合疫苗（PCV13）替代10价肺炎球菌结合疫苗（PCV10）的成本效益分析》的回应
Hum Vaccin Immunother. 2022 Dec 31;18(1):1894898. doi: 10.1080/21645515.2021.1894898. Epub 2021 May 19.
2
Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.致 Gomez 等人对 Johnna Perdrizet 等人文章的回应的回复信。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1917237. doi: 10.1080/21645515.2021.1917237. Epub 2021 Apr 28.
3
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.在巴西婴儿中用13价肺炎球菌结合疫苗（PCV13）替代10价肺炎球菌结合疫苗（PCV10）的成本效益分析。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1162-1172. doi: 10.1080/21645515.2020.1809266. Epub 2020 Sep 23.
4
Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.在韩国，13价肺炎球菌结合疫苗与10价肺炎球菌结合疫苗的国家免疫规划的成本效益比较。
Hum Vaccin Immunother. 2021 Mar 4;17(3):909-918. doi: 10.1080/21645515.2020.1796426. Epub 2020 Aug 12.
5
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.加拿大 13 价和 10 价肺炎球菌结合疫苗 2+1 剂量接种的成本效益。
BMC Infect Dis. 2012 Apr 24;12:101. doi: 10.1186/1471-2334-12-101.
6
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.秘鲁10价和13价肺炎球菌结合疫苗的成本效益分析。
Vaccine. 2015 May 7;33 Suppl 1:A154-66. doi: 10.1016/j.vaccine.2014.12.039.
7
Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.肯尼亚儿童 10 价和 13 价肺炎球菌结合疫苗的健康效益和成本效益评估。
PLoS One. 2013 Jun 24;8(6):e67324. doi: 10.1371/journal.pone.0067324. Print 2013.
8
Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.丹麦和瑞典 10 价与 13 价肺炎球菌结合疫苗的成本效益分析。
Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.
9
Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.马来西亚和香港地区婴儿普遍常规接种肺炎球菌疫苗的成本效益分析。
Hum Vaccin Immunother. 2016;12(2):403-16. doi: 10.1080/21645515.2015.1067351.
10
Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'".评论戈麦斯等人的文章“对 Wasserman 等人（2018 年）文章的回应：对墨西哥使用 13 价肺炎球菌结合疫苗替代 10 价疫苗的持续使用进行建模”。
Hum Vaccin Immunother. 2019;15(3):572-574. doi: 10.1080/21645515.2018.1558691. Epub 2019 Jan 18.
本文引用的文献
1
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.在巴西婴儿中用13价肺炎球菌结合疫苗（PCV13）替代10价肺炎球菌结合疫苗（PCV10）的成本效益分析。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1162-1172. doi: 10.1080/21645515.2020.1809266. Epub 2020 Sep 23.
2
Trends in all-cause pneumonia and otitis media in children aged <2 years following pneumococcal conjugate vaccine introduction in Colombia.在哥伦比亚引入肺炎球菌结合疫苗后，2岁以下儿童全因性肺炎和中耳炎的发病趋势。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1173-1180. doi: 10.1080/21645515.2020.1805990. Epub 2020 Sep 23.
3
Estimated Annual Health and Cost Impact of PHiD-CV Immunization Program in Brazil.巴西 PHiD-CV 免疫计划的年度健康和成本影响预估。
Pediatr Infect Dis J. 2019 Oct;38(10):e260-e265. doi: 10.1097/INF.0000000000002436.
4
Emergence of serotype 19A Streptococcus pneumoniae after PCV10 associated with a ST320 in adult population, in Porto Alegre, Brazil.巴西阿雷格里港人群中，PCV10 相关 19A 型肺炎链球菌血清型的出现与 ST320 有关。
Epidemiol Infect. 2019 Jan;147:e93. doi: 10.1017/S0950268819000013.
5
Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil.巴西引入10价肺炎球菌结合疫苗（PCV10）后儿童全因性中耳炎相关门诊就诊次数减少。
PLoS One. 2017 Jun 8;12(6):e0179222. doi: 10.1371/journal.pone.0179222. eCollection 2017.
6
Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review.10价和13价肺炎球菌结合疫苗对拉丁美洲国家5岁以下儿童住院率和死亡率的影响及效果：一项系统评价
PLoS One. 2016 Dec 12;11(12):e0166736. doi: 10.1371/journal.pone.0166736. eCollection 2016.
7
Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada.三种肺炎球菌结合疫苗预防加拿大魁北克侵袭性肺炎球菌疾病的有效性
Vaccine. 2015 May 28;33(23):2684-9. doi: 10.1016/j.vaccine.2015.04.005. Epub 2015 Apr 15.
8
Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study.十价肺炎球菌结合疫苗对芬兰儿童侵袭性肺炎球菌疾病的影响——一项基于人群的研究
PLoS One. 2015 Mar 17;10(3):e0120290. doi: 10.1371/journal.pone.0120290. eCollection 2015.
9
Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.十价肺炎球菌结合疫苗在巴西预防侵袭性肺炎球菌病的效果：一项匹配病例对照研究。
Lancet Respir Med. 2014 Jun;2(6):464-71. doi: 10.1016/S2213-2600(14)70060-8. Epub 2014 Apr 10.
10
Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1.建立良好研究实践模型——概述：ISPOR-SMDM 建立良好研究实践工作组 1 的报告。
Med Decis Making. 2012 Sep-Oct;32(5):667-77. doi: 10.1177/0272989X12454577.
Zotero 插件